AnaptysBio, Inc. Forecasted to Post Q1 2024 Earnings of ($1.41) Per Share (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share estimates for AnaptysBio in a report released on Tuesday, April 16th. Leerink Partnrs analyst D. Risinger anticipates that the biotechnology company will post earnings per share of ($1.41) for the quarter. Leerink Partnrs currently has a "Outperform" rating on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($6.25) per share. Leerink Partnrs also issued estimates for AnaptysBio's Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, FY2024 earnings at ($5.71) EPS, Q1 2025 earnings at ($1.91) EPS, Q2 2025 earnings at ($1.86) EPS, Q3 2025 earnings at ($1.85) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($6.37) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at ($3.95) EPS and FY2028 earnings at ($3.39) EPS.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) EPS for the quarter, topping analysts' consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. The company had revenue of $9.01 million for the quarter, compared to analysts' expectations of $3.28 million.

A number of other brokerages have also recently commented on ANAB. Wedbush upgraded AnaptysBio from a "neutral" rating to an "outperform" rating and raised their price target for the stock from $20.00 to $34.00 in a research report on Tuesday, March 12th. SVB Leerink began coverage on AnaptysBio in a research note on Tuesday. They issued an "outperform" rating and a $47.00 price objective on the stock. JPMorgan Chase & Co. reduced their price objective on AnaptysBio from $30.00 to $28.00 and set a "neutral" rating on the stock in a research note on Monday, April 1st. Wells Fargo & Company began coverage on AnaptysBio in a research note on Thursday, April 11th. They issued an "overweight" rating and a $56.00 price objective on the stock. Finally, Piper Sandler began coverage on AnaptysBio in a research note on Friday, February 16th. They issued an "overweight" rating and a $80.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, AnaptysBio has a consensus rating of "Moderate Buy" and an average target price of $46.22.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB traded down $1.64 during mid-day trading on Thursday, reaching $19.83. The company had a trading volume of 363,855 shares, compared to its average volume of 313,406. AnaptysBio has a one year low of $13.36 and a one year high of $27.50. The firm has a market cap of $530.65 million, a price-to-earnings ratio of -3.26 and a beta of -0.30. The business's 50-day simple moving average is $23.31 and its 200 day simple moving average is $20.54.

Institutional Investors Weigh In On AnaptysBio

Hedge funds have recently added to or reduced their stakes in the business. Woodline Partners LP increased its holdings in shares of AnaptysBio by 125.1% during the second quarter. Woodline Partners LP now owns 1,034,549 shares of the biotechnology company's stock valued at $21,043,000 after acquiring an additional 574,987 shares in the last quarter. First Light Asset Management LLC increased its holdings in shares of AnaptysBio by 56.4% during the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company's stock valued at $26,500,000 after acquiring an additional 446,372 shares in the last quarter. Eventide Asset Management LLC bought a new stake in shares of AnaptysBio during the third quarter valued at approximately $7,669,000. Millennium Management LLC increased its holdings in shares of AnaptysBio by 1,050.7% during the fourth quarter. Millennium Management LLC now owns 322,802 shares of the biotechnology company's stock valued at $10,004,000 after acquiring an additional 294,750 shares in the last quarter. Finally, Palo Alto Investors LP increased its holdings in shares of AnaptysBio by 59.3% during the fourth quarter. Palo Alto Investors LP now owns 686,882 shares of the biotechnology company's stock valued at $14,713,000 after acquiring an additional 255,658 shares in the last quarter.

Insider Activity

In related news, CEO Daniel Faga sold 145,940 shares of AnaptysBio stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $22.78, for a total value of $3,324,513.20. Following the transaction, the chief executive officer now directly owns 752,087 shares of the company's stock, valued at $17,132,541.86. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other AnaptysBio news, insider Eric J. Loumeau sold 5,000 shares of AnaptysBio stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the sale, the insider now directly owns 3,240 shares in the company, valued at $81,000. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Daniel Faga sold 145,940 shares of AnaptysBio stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $22.78, for a total value of $3,324,513.20. Following the completion of the sale, the chief executive officer now owns 752,087 shares of the company's stock, valued at $17,132,541.86. The disclosure for this sale can be found here. Over the last three months, insiders have sold 157,005 shares of company stock valued at $3,586,199. 35.50% of the stock is currently owned by corporate insiders.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.